港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

生物医药B类股

437.197

+6.7341.56%

涨家数：13

跌家数：17

平家数：4

市盈率：- -

高：444.607

开：430.463

低：424.474

收：430.463

数据加载中...

【拓新药业：全资子公司奥拉帕利原料药获得上市申请批准通知书】拓新药业(301089.SZ)公告称，公司全资子公司新乡制药股份有限公司的奥拉帕利原料药收到国家药品监督管理局签发的《化学原料药上市申请批准通知书》，并批准注册。奥拉帕利主要用于治疗携带胚系或体系BRCA突变的晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌。此次批准将丰富公司产品线，提升市场竞争力，对国内市场产生积极影响。但需注意医药产品销售受市场、政策、环境变化等不确定因素影响，存在销售不达预期的风险。

天康生物：目前并无将主营业务转接至天康制药的计划

东曜药业-B盘中异动下午盘股价大涨9.89%报2.000港元

港股异动 | 科济药业-B(02171)涨近7% Claudin18.2 CAR-T纳入突破性治疗药物品种有望上半年申请上市

康宁杰瑞制药-B盘中异动下午盘股价大跌5.29%

沛嘉医疗－Ｂ(09996)股价显著上升12.23%，现价港币$4.68

阿斯达克财经

同源康医药-B盘中异动下午盘股价大跌6.45%报29.000港元

欧康维视生物-B盘中异动股价大涨5.15%报4.900港元

创新药概念震荡拉升热景生物涨超15%创2年多新高

南方财经网

【欧普康视等成立眼视光科技公司含诊所服务业务】公开资料显示，近日，郑州欧普康视眼视光科技有限公司成立，法定代表人为闫霞，注册资本100万元，经营范围包含：第一类医疗器械销售；诊所服务；电子产品销售；文具用品零售；体育用品及器材零售；医院管理；企业管理；品牌管理等。股权数据显示，该公司由河南一眸科技有限公司、欧普康视旗下欧普康视投资有限公司共同持股。

心通医疗-B(02160)上涨20.79%，报1.22元/股

华领医药－Ｂ(02552)股价下跌5.328%，现价港币$2.31

阿斯达克财经

医药外包概念股集体走强维亚生物涨6.77% 机构指AI技术渗透加速CXO产业范式革新

荣昌生物盘中异动下午盘急速拉升5.19%

稀缺科创生物医药新股！全球竞争优势明显，利润3年翻了近四倍

科济药业-B盘中异动下午盘急速上涨5.00%报15.960港元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news?page=7"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":437.19687,"timestamp":1741334919603,"preClose":430.4633,"halted":0,"volume":156813444,"delay":0,"changeRate":0.015643,"change":6.733582,"pbRate":3.43319,"amount":2812448156,"amplitude":0.046771,"prevYearClose":331.1933,"fiveDayClose":411.011,"twentyDayClose":335.39,"turnoverRate":0.005967,"marketCap":244193759232,"floatMarketCap":230149584960,"peRate":-17.305245},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":444.6071,"amplitude":0.046771,"preClose":430.4633,"low":424.47403,"pbRate":"3.43319","latestPrice":437.19687,"volume":156813444,"delay":0,"open":430.4633,"prevYearClose":331.1933,"prevWeekClose":411.011,"prevMonthClose":411.011,"prevQuarterClose":331.193,"fiveDayClose":411.011,"twentyDayClose":335.39,"sixtyDayClose":340.535,"secType":"PLATE","market":"HK","turnoverRate":0.005967,"peRate":-17.305245,"marketCap":244193759232,"floatMarketCap":230149584960,"timestamp":1741334919603,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":13,"down":17,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:16,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517182501","title":"【拓新药业：全资子公司奥拉帕利原料药获得上市申请批准通知书】拓新药业(301089.SZ)公告称，公司全资子公司新乡制药股份有限公司的奥拉帕利原料药收到国家药品监督管理局签发的《化学原料药上市申请批准通知书》，并批准注册。奥拉帕利主要用于治疗携带胚系或体系BRCA突变的晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌。此次批准将丰富公司产品线，提升市场竞争力，对国内市场产生积极影响。但需注意医药产品销售受市场、政策、环境变化等不确定因素影响，存在销售不达预期的风险。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517182501","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517182501?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 15:45","pubTimestamp":1741247149,"startTime":"0","endTime":"0","summary":"拓新药业(301089.SZ)公告称，公司全资子公司新乡制药股份有限公司的奥拉帕利原料药收到国家药品监督管理局签发的《化学原料药上市申请批准通知书》，并批准注册。奥拉帕利主要用于治疗携带胚系或体系BRCA突变的晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌。此次批准将丰富公司产品线，提升市场竞争力，对国内市场产生积极影响。但需注意医药产品销售受市场、政策、环境变化等不确定因素影响，存在销售不达预期的风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06154548559054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01477","301089","BK1515","159938","09939","BK1574","BK1161","BK1191","BK0239"],"gpt_icon":0},{"id":"2517848601","title":"天康生物：目前并无将主营业务转接至天康制药的计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2517848601","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517848601?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 15:37","pubTimestamp":1741246653,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1191","BK0210","BK0016","01477","BK0188","BK0238","BK0028","002100","BK1574","BK0046","BK0168","BK0195","BK0027","BK0201","000061"],"gpt_icon":0},{"id":"2517846401","title":"东曜药业-B盘中异动 下午盘股价大涨9.89%报2.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517846401","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517846401?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 15:27","pubTimestamp":1741246036,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘15时27分，东曜药业-B股票出现波动，股价大幅拉升9.89%。截至发稿，该股报2.000港元/股，成交量50.88万股，换手率0.07%，振幅10.99%。资金方面，该股资金流入73.5648万港元，流出22.0408万港元。东曜药业-B股票所在的生物技术行业中，整体涨幅为0.55%。股价大跌之后，今日上午，乐普生物随即发布公告回应新药上市不顺利的原因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306152717abeaeb8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306152717abeaeb8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01875","BK1161"],"gpt_icon":0},{"id":"2517189469","title":"港股异动 | 科济药业-B(02171)涨近7% Claudin18.2 CAR-T纳入突破性治疗药物品种 有望上半年申请上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2517189469","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517189469?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 15:14","pubTimestamp":1741245299,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B涨近7%，截至发稿，涨4.74%，报15.92港元，成交额1.01亿港元。消息面上，科济药业近日宣布，公司自主研发的舒瑞基奥仑赛注射液已被国家药品监督管理局药品审评中心纳入突破性治疗药物品种名单，拟定适应症为既往接受过至少二线治疗失败的Claudin18.2表达阳性的晚期胃/食管胃结合部腺癌。公司预计将于2025年上半年向国家药品监督管理局递交舒瑞基奥仑赛注射液的新药上市申请。此次增资完成后，公司的权益将由100%稀释至92%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4022","BK1161","BK1585","BK1574","02171","BK1587","BK4230","CAR"],"gpt_icon":0},{"id":"2517186283","title":"康宁杰瑞制药-B盘中异动 下午盘股价大跌5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517186283","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517186283?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 14:58","pubTimestamp":1741244288,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘14时58分，康宁杰瑞制药-B股票出现波动，股价快速下挫5.29%。康宁杰瑞制药-B股票所在的生物技术行业中，整体涨幅为0.47%。消息层面，截至14时58分，《康宁杰瑞制药绩后大涨！首次实现年度盈利》资讯为影响康宁杰瑞制药-B的重要信息。康宁杰瑞制药绩后大涨超10%，领涨恒生医药ETF持仓股，再鼎医药、巨子生物、诺诚健华等涨幅靠前。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306145809a261f929&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306145809a261f929&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2517868251","title":"沛嘉医疗－Ｂ(09996)股价显著上升12.23%，现价港币$4.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2517868251","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517868251?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 14:40","pubTimestamp":1741243200,"startTime":"0","endTime":"0","summary":"[上升股]沛嘉医疗－Ｂ(09996) 股价在下午02:40比前收市价显著上升12.23%，现股价为港币$4.68。至目前为止，今日最高价为$4.68，而最低价为$4.21。总成交量为347.3万股，总成交金额为港币$1.573千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2503068824/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","09996","BK1583","159891","BK1100"],"gpt_icon":0},{"id":"2517186478","title":"同源康医药-B盘中异动 下午盘股价大跌6.45%报29.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517186478","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517186478?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 14:23","pubTimestamp":1741242194,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘14时23分，同源康医药-B股票出现波动，股价急速跳水6.45%。截至发稿，该股报29.000港元/股，成交量39.85万股，换手率0.11%，振幅9.52%。资金方面，该股资金流入665.168万港元，流出549.195万港元。同源康医药-B股票所在的生物技术行业中，整体涨幅为0.51%。同源康医药-B公司简介：浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306142314abeada0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306142314abeada0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02410","BK1574","09939","BK1161","BK1515"],"gpt_icon":0},{"id":"2517183534","title":"欧康维视生物-B盘中异动 股价大涨5.15%报4.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517183534","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517183534?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 14:13","pubTimestamp":1741241592,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘14时13分，欧康维视生物-B股票出现波动，股价快速上涨5.15%。截至发稿，该股报4.900港元/股，成交量183.45万股，换手率0.22%，振幅5.15%。资金方面，该股资金流入534.561万港元，流出211.619万港元。欧康维视生物-B股票所在的生物技术行业中，整体涨幅为0.48%。欧康维视生物-B公司简介：欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306141312a261ef0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306141312a261ef0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2517883931","title":"创新药概念震荡拉升 热景生物涨超15%创2年多新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2517883931","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517883931?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:56","pubTimestamp":1741240575,"startTime":"0","endTime":"0","summary":"南方财经3月6日电，创新药概念震荡拉升，午后热景生物拉升涨超15%，股价创2年多新高，博瑞医药涨近10%，诺思格、一品红、荣昌生物、艾力斯、药明康德等涨幅靠前。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503063338418745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2517334188","title":"【欧普康视等成立眼视光科技公司 含诊所服务业务】 公开资料显示，近日，郑州欧普康视眼视光科技有限公司成立，法定代表人为闫霞，注册资本100万元，经营范围包含：第一类医疗器械销售；诊所服务；电子产品销售；文具用品零售；体育用品及器材零售；医院管理；企业管理；品牌管理等。股权数据显示，该公司由河南一眸科技有限公司、欧普康视旗下欧普康视投资有限公司共同持股。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517334188","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517334188?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:55","pubTimestamp":1741240523,"startTime":"0","endTime":"0","summary":"公开资料显示，近日，郑州欧普康视眼视光科技有限公司成立，法定代表人为闫霞，注册资本100万元，经营范围包含：第一类医疗器械销售；诊所服务；电子产品销售；文具用品零售；体育用品及器材零售；医院管理；企业管理；品牌管理等。股权数据显示，该公司由河南一眸科技有限公司、欧普康视旗下欧普康视投资有限公司共同持股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06135548557348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1222","BK1574","09996","BK1583","09997","300595","159883","BK0251","BK1100"],"gpt_icon":0},{"id":"2517188327","title":"心通医疗-B(02160)上涨20.79%，报1.22元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2517188327","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517188327?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:51","pubTimestamp":1741240306,"startTime":"0","endTime":"0","summary":"3月6日，心通医疗-B盘中上涨20.79%，截至13:51，报1.22元/股，成交2516.96万元。心通医疗是一家中国领先的医疗器械企业，主要从事结构性心脏病领域的经导管和手术解决方案的研发和商业化，产品包括VitaFlow系列经导管主动脉瓣植入产品、经导管二尖瓣治疗产品、经导管三尖瓣治疗产品、外科瓣膜产品和手术配件等。截至2024年中报，心通医疗-B营业总收入2.23亿元、净利润-5646.1万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/06135148557357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1100","02160","BK1583"],"gpt_icon":0},{"id":"2517188442","title":"华领医药－Ｂ(02552)股价下跌5.328%，现价港币$2.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2517188442","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517188442?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:50","pubTimestamp":1741240200,"startTime":"0","endTime":"0","summary":"[下跌股]华领医药－Ｂ(02552) 股价在下午01:50比前收市价下跌5.328%，现股价为港币$2.31。至目前为止，今日最高价为$2.59，而最低价为$2.31。总成交量为756.05万股，总成交金额为港币$1.857千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2503062736/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1191","02552"],"gpt_icon":0},{"id":"2517512188","title":"医药外包概念股集体走强 维亚生物涨6.77% 机构指AI技术渗透加速CXO产业范式革新","url":"https://stock-news.laohu8.com/highlight/detail?id=2517512188","media":"金吾资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517512188?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:48","pubTimestamp":1741240123,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念股集体走强，截至发稿，维亚生物 涨6.77%，康龙化成涨3.92%，泰格医药和药明康德涨3.24%，药明生物涨2.38%消息面上，国泰君安发布研报称，AI技术渗透加速CXO产业范式革新。AI技术在生物医药领域深度应用有望重构CXO产业价值链。全球药企降本增效诉求升级，叠加AI技术成熟度提升，驱动CXO企业加速智能化转型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306134913963bb5f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306134913963bb5f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02359","BK1515","01873","BK1161","BK1574","BK1576","03759","BK1141","03347","09939"],"gpt_icon":0},{"id":"2517890030","title":"荣昌生物盘中异动 下午盘急速拉升5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517890030","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517890030?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:34","pubTimestamp":1741239266,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘13时34分，荣昌生物股票出现波动，股价急速上涨5.19%。截至发稿，该股报17.840港元/股，成交量271.55万股，换手率1.43%，振幅4.95%。荣昌生物股票所在的生物技术行业中，整体涨幅为0.51%。荣昌生物公司简介：研发、生产和销售医药产品、诊断试剂产品,以及进行与上述产品及其研发相关的技术服务、技术转让,货物或技术进出口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306133426989e1cd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306133426989e1cd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","BK1161","BK1574","LU1969619763.USD","BK1583","09995"],"gpt_icon":0},{"id":"2517092188","title":"稀缺科创生物医药新股！全球竞争优势明显，利润3年翻了近四倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2517092188","media":"海豚音","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517092188?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:21","pubTimestamp":1741238460,"startTime":"0","endTime":"0","summary":"能否成为下一个生物医药趋势牛股，且看海豚今日为你深度剖析！微球第一股纳微科技采用耗材+仪器双轮驱动，除了色谱介质外还涉足分析色谱仪、平板显示用微球、体外诊断用微球等领域，相比之下赛分科技则主要聚焦于药物及生物大分子分离纯化液相色谱材料领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-03-06/doc-inenswii7959986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","159938","09939","BK1574","BK1161","000683.SH"],"gpt_icon":0},{"id":"2517318854","title":"科济药业-B盘中异动 下午盘急速上涨5.00%报15.960港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517318854","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517318854?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:11","pubTimestamp":1741237872,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘13时11分，科济药业-B股票出现异动，股价快速拉升5.00%。截至发稿，该股报15.960港元/股，成交量434.15万股，换手率0.76%，振幅5.00%。科济药业-B股票所在的生物技术行业中，整体涨幅为0.35%。2月26日，科济药业公告披露，旗下优恺泽生物完成珠海软银主导的8000万元战略融资，对应估值达10亿元。科济药业的转型之路颇具行业启示意义。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306131112963baef8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306131112963baef8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1587","BK1161","BK1585","02171"],"gpt_icon":0}],"pageSize":16,"totalPage":45,"pageCount":7,"totalSize":708}]}}